The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment

NCT ID: NCT05797181

Last Updated: 2024-07-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-07

Study Completion Date

2023-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, it was aimed to evaluate the effectiveness of medical nutrition therapy to be applied to patients with sarcopenic obesity receiving peritoneal dialysis treatment by measuring anthropometric measurements and blood parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Efficacy of medical nutrition therapy in patients with sarcopenic obesity receiving peritoneal dialysis treatment, general information form after patients filled in the voluntary consent form, SARC-F questionnaire as sarcopenia screening test, International Physical Activity Questionnaire (IPAQ), muscle mass, muscle strength, physical performance, BIA measurement, anthropometric measurements, laboratory findings and three-day food consumption records will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritoneal Dialysis Complication Sarcopenic Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dietary and Behavioral Change Group

The experimental group will be required to adhere to a diet consisting of a 10-15% reduction in carbohydrate and a 1.2-1.4 g/kg body weight/day intake of protein.

The participants will receive 4 times face-to-face meetings (on the first day and on week 1,5 and 9).

Each face-to-face interview will last approximately 30 minutes. During the interview researcher will help the participants to determine their nutritional behaviors, plan and implement the diet.

Group Type EXPERIMENTAL

medical nutrition therapy in kidney diseases

Intervention Type OTHER

Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

medical nutrition therapy in kidney diseases

Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteering to participate in research
* Be between the ages of 18-70
* To receive peritoneal dialysis treatment and to come to the hospital regularly once a month for treatment

Exclusion Criteria

* Presence of any other disease that causes muscle wasting
* Patients using any supplement or enteral product in their diet
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Atlas University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ayşe Betül Demirbaş

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ayşe Betül Demirbaş

Role: PRINCIPAL_INVESTIGATOR

Atlas University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marmara University

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABDemirbasPD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Weight Management of Dialysis Patients
NCT06333574 NOT_YET_RECRUITING NA
L-Cysteine in Peritoneal Dialysis
NCT02050139 COMPLETED PHASE2
Lung Ultrasound in PD Patients
NCT03801044 COMPLETED